Origami Therapeutics, Inc.

@BiotechHannes @LongevityTech @BethJHoffman Not if you focus on true small molecules!

@LongevityTech @OrigamiTX @BethJHoffman No contest. Autophagy beats proteasome inhibition for neuronal proteinopathies. BBB delivery is the real bottleneck.

Origami Therapeutics CEO on harnessing autophagy to precisely target disease-causing proteins in the brain. vist.ly/4vj8c @OrigamiTX @BethJHoffman #longevity #biotech #neuro #neurodegeneration #proteindegradation

Our CEO, @BethJHoffman shares some perspectives on how the work at Origami Therapeutics applies to improving brain healthspan in the latest issue of @LongevityTech longevity.technology/news/targeting…

Our CEO, @BethJHoffman shares some insights about partnering and the recent agreement with Ipsen. clinicalleader.com/doc/what-to-lo…

Happy International Women's Day from HDSA! Let's take a moment to honor the incredible women in our lives who inspire us every day with their courage and determination. Tag a woman who inspires you! #InternationalWomensDay #HDSAFamily #FamilyIsEverything

Here's a link to a very nice interview with our CEO @BethJHoffman about our recent partnership with Ipsen in the @SDbusiness linkedin.com/feed/update/ur…

A nice interview with our CEO, @BethJHoffman bioxconomy.com/partnering/ori…

Very excited to announce this important partnership with Ipsen. Their strong rare neuroscience heritage meshes with our focus on developing breakthrough therapeutics for these diseases to accelerate bringing treatments to patients. @BethJHoffman businesswire.com/news/home/2026…

Save the Date for the 41st Annual HDSA Convention, June 25-27th, in Phoenix, AZ! Registration coming soon. Stay tuned on all platforms. #HDSAConvention #FamilyIsEverything #HuntingtonsDisease #LetsTalkAboutHD

🧵French biopharmaceutical Ipsen has entered a global collaboration and option agreement with San Diego-based biotech Origami Therapeutics @OrigamiTX to advance a small-molecule protein degrader program targeting a rare inherited neurodegenerative disorder european-biotechnology.com/latest-news/or…

HDSA offers support groups for everyone impacted by Huntington’s disease, including individuals living with HD, caregivers, and people at risk. If you're looking for a support group near you, visit: hdsa.org/.../community.… #LetsTalkAboutHD #HuntingtonsDisease #HDFamily

Incredibly proud of the presentation of our CEO, @BethJHoffman and honored to be named a prize winner at the New Orleans BioInnovation Center 2025 BioChallenge. Inspired to keep working to deliver innovative treatments to patients and their care givers. neworleansbio.com/junebrain-name…

We are very pleased that Origami Therapeutics has been selected as a finalist at the NOBIC (@neworleansbio ) BioChallenge Pitch Competition, October 30. You can watch our CEO, Beth J Hoffman present via the link provided in the PR. neworleansbio.com/nobic-announce…

Our CEO, @BethJHoffman will be traveling to New Orleans as a finalist in NOBIC Biochallenge, this year focusing on CNS therapies!

🌟 What a start to #BioFuture2025! This year’s conference began with our “Big Think” Fireside Chat featuring James Flynn (@Deerfield) & Sara Jane Demy, followed by Spotlight Panels covering #cancer and #brainhealth innovation. 🗓️ See the full agenda: biofuture.com/agenda

An exciting start to #BioFuture2025 in #NYC! Our CEO, Connor Glass, shared how we're bridging the gap between #neuroscience breakthroughs & real-world impact. Grateful to @demy_sara and #DemyColton for bringing together global leaders driving progress in patient outcomes.

Our CEO @BethJHoffman is attending #BioFuture2025 and joining the Spotlight Panel, “Rewiring Minds: Breakthroughs in Brain & CNS Health” on October 13.